Humacyte
HUMA
21 hedge funds and large institutions have $44.7M invested in Humacyte in 2020 Q4 according to their latest regulatory filings, with 21 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
42.59% more ownership
Funds ownership: 0% → 42.59% (+43%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OP
Omni Partners
London,
United Kingdom
|
+$10.7M |
| 2 |
BFM
Boothbay Fund Management
New York
|
+$6.05M |
| 3 |
Tudor Investment Corp
Stamford,
Connecticut
|
+$5.38M |
| 4 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
+$4.46M |
| 5 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
+$2.97M |
Top Sellers
HUMA Hedge Fund Activity: Q4 2020 in Review
21 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Humacyte (HUMA) for Q4 2020, worth a combined $44.7M.
Buyers outnumbered sellers: 21 funds opened new HUMA positions and 0 closed out — a net gain of 21 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Omni Partners, opening a new position worth an estimated $10.7M.
- 21 institutional investors held Humacyte (HUMA) as of Q4 2020, up from 0 in Q3 2020.
- Funds reported $44.7M of Humacyte stock for Q4 2020.
- 21 funds opened new Humacyte positions in Q4 2020 and 0 closed out, a net change of +21 holders.
- The largest Humacyte buyer in Q4 2020 was Omni Partners, an estimated $10.7M added.
Based on aggregated 13F filings for Q4 2020.